Presence of Clostridioides difficile and multidrug-resistant healthcare-associated pathogens in stool specimens from hospitalized patients in the USA

Tickler, Isabella A.; Cruz, Caitlin M. dela; Obradovich, Anne E.; Goering, Richard V; Dewell, Scott; Le, Victoria M.; Tenover, Fred C.; Anderson, Julie Renee; Banaei, Niaz; Bankowski, Matthew J.; Dill, Jamie Lynne; Harrington, Amanda; Henthorne, Mary Ann; Klutts, J. Stacey; Koyamatsu, Terrie; Overcast, Rose; Rekasius, Violeta; Rojtman, Albert

doi:10.1016/j.jhin.2020.07.003

Cited by 4 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the remaining sixteen studies, two were excluded for not reporting dat Clostridioides difficile and Enterococcus spp. 's interaction in the gut microbiota [10 Therefore, 14 studies were included in this systematic review (Figure 1) [1,[12][13][14][15][16][17][18][19][20][21][22][23][24]. O 14 included studies, 3 studies evaluated Enterococcus spp.…”

Section: Study Descriptionmentioning

confidence: 99%

“…'s interaction in the gut microbiota [10,11]. Therefore, 14 studies were included in this systematic review (Figure 1) [1,[12][13][14][15][16][17][18][19][20][21][22][23][24]. Of the 14 included studies, 3 studies evaluated Enterococcus spp.…”

Section: Study Descriptionmentioning

confidence: 99%

“…intestinal burden as a risk factor for CDI onset [1,[15][16][17], 3 studies reported the prevalence of vancomycin-resistant Enterococcus spp. in CDI patients [18][19][20] and 4 studies evaluated the effect of CDI antimicrobial treatment on the occurrence of vancomycin-resistant Enterococcus spp. colonization [21][22][23][24].…”

Section: Study Descriptionmentioning

confidence: 99%

See 2 more Smart Citations

Clostridioides difficile and Enterococci’s Interplay in the Human Gut: Bacterial Alliance or Competition? A Systematic Literature Review

Granata,

Schiavone,

Taglietti

et al. 2023

JCM

View full text Add to dashboard Cite

Clostridioides difficile and Enterococcus spp. are two common bacterial pathogens populating the human microbiota. We possess scant data on how Clostridioides difficile interacts with Enterococcus spp. in the gut microbiota in subjects colonized with Clostridioides difficile or during a Clostridioides difficile infection. We carried out a systematic review of studies on Enterococcus spp. and Clostridioides difficile’s interaction in the gut microbiota and on the effect of Enterococcus spp. gut colonization on CDI development. Studies on Enterococcus spp. and Clostridioides difficile’s interaction in the gut microbiota and on the effect of Enterococcus spp. gut colonization on CDI were searched using the search terms “clostridium”, “clostridioides”, “difficile” and “enterococcus” on the MEDLINE and SCOPUS databases. PubMed was searched until 1 May 2023. An English language restriction was applied. The risk of bias in the included studies was not assessed. Quantitative and qualitative information was summarized in textual descriptions. Fourteen studies, published from August 2012 to November 2022, on Clostridioides difficile and Enterococcus spp.’s interaction in the gut microbiota met the inclusion criteria. The studies included in our systematic review reported evidence that the Enterococcus spp. intestinal burden represents a risk factor for the occurrence of CDI. There is supporting evidence that Enterococcus spp. play a role in CDI development and clinical outcomes.

show abstract

Section: Study Descriptionmentioning

confidence: 99%

Section: Study Descriptionmentioning

confidence: 99%

See 1 more Smart Citation

Clostridioides difficile and Enterococci’s Interplay in the Human Gut: Bacterial Alliance or Competition? A Systematic Literature Review

Granata,

Schiavone,

Taglietti

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…The charges for the same treatment are much higher than the actual costs because they represent the initial value hospitals use to start negotiations with insurance parties. Prevalence of MDRO carriage in these analyses was set at 11.3 %, as found in literature (including MRSA, carbapenem-resistant enterobacteriaceae [CRE] and vancomycin-resistant enterococci [VRE], but not extended spectrum beta-lactamase-producing microorganisms) [17,18].…”

Section: Us Cost Analysesmentioning

confidence: 99%

“…In countries where ESBL-producing microorganisms are more prevalent, screening for carriage of these microorganisms is sometimes omitted. The MDRO prevalence rate used in the cost analyses for the US situation was also based on studies not involving ESBL carriage [17,18]. Moreover, the GeneXpert method as used in crossover Scenario 2 is not capable of identifying ESBL-producing microorganisms, but only MRSA, VRE and CRE.…”

Section: E577mentioning

confidence: 99%

Single-use duodenoscopes compared with reusable duodenoscopes in patients carrying multidrug-resistant microorganisms: a break-even cost analysis

et al. 2023

View full text Add to dashboard Cite

Background and study aims Single-use duodenoscopes can prevent transmission of microorganisms through contaminated reusable duodenoscopes. Concerns regarding their economic and environmental impact impede the transition to single-use duodenoscopes. This study investigated the costs associated with two scenarios in which single-use duodenoscopes are used in patients carrying multidrug-resistant microorganisms (MDROs). Methods Break-even costs for single-use duodenoscopes were calculated for two scenarios in which patients were screened for MDRO carriage before undergoing endoscopic retrograde cholangiopancreatography (ERCP). Only direct costs related to the endoscopy were taken into consideration. In Scenario 1, patients were screened through microbiological culturing with a lag time in receiving the test result. In Scenario 2, screening was performed using GeneXpert analysis providing a rapid read-out. Calculations were performed using data from a Dutch tertiary care center and also with US healthcare data. Results In the Dutch situation, single-use duodenoscopes needed to be priced at a maximum of € 140 to € 250 to break-even. In the US analyses, break-even costs varied widely, depending on the duodenoscope-associated infection costs used, ERCP volume, and infection risk. The break-even costs in Scenario 1 ranged between $78.21 and $2,747.54 and in Scenario 2, between $248.89 and $2,209.23. Conclusions This study showed that a crossover scenario in which single-use duodenoscopes are only used in patients carrying MDROs could be an economically viable alternative to a complete transition to single-use duodenoscopes. In the Dutch setting, single-use duodenoscopes need to be priced much lower than in the United States to reach a per-procedure cost that is comparable with a scenario using reusable duodenoscopes exclusively.

show abstract

One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals

Monnier¹,

Candela²,

Mizrahi³

et al. 2022

Journal of Hospital Infection

View full text Add to dashboard Cite

Presence of Clostridioides difficile and multidrug-resistant healthcare-associated pathogens in stool specimens from hospitalized patients in the USA

Cited by 4 publications

References 20 publications

Clostridioides difficile and Enterococci’s Interplay in the Human Gut: Bacterial Alliance or Competition? A Systematic Literature Review

Clostridioides difficile and Enterococci’s Interplay in the Human Gut: Bacterial Alliance or Competition? A Systematic Literature Review

Single-use duodenoscopes compared with reusable duodenoscopes in patients carrying multidrug-resistant microorganisms: a break-even cost analysis

One-day prevalence of asymptomatic carriage of toxigenic and non-toxigenic Clostridioides difficile in 10 French hospitals

Contact Info

Product

Resources

About